ACURA PHARMACEUTICALS, INC.

ACURA PHARMACEUTICALS, INC.

Previous company name
HALSEY DRUG CO., INC.
Name change date
8/13/2004
Company Overview
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of Aversion (abuse deterrent) Technology and related product candidates. The company’s business started in 1935 and has its registered headquarters located in Palatine, Illinois.
Product candidates developed with Aversion Technology and containing opioid analgesic active ingredients are intended to treat pain. OxyADF Tablets, the company’s lead product candidate with Aversion Technology, are orally administered immediate-release tablets containing oxycodone HCl as the sole active analgesic ingredient. Acura Pharmaceuticals’ registered trademarks are Aversion, Axiom Pharmaceutical Corporation, and Acura Pharmaceuticals.
The company conducts research, development, laboratory, stability, quality assurance, manufacturing, warehousing and other activities relating to the Aversion Technology at its Culver, Indiana operations facility. Its facility is registered by the Drug Enforcement Agency (“DEA”) to perform research, development and the manufacture of certain Schedule II – V controlled substances in bulk and finished dosage forms.
Business Summary
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.
Description and history
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.

Aversion Technology is a platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing potentially abuseable active ingredients. The company focuses to utilize its Aversion Technology with opioid analgesics administered in tablet or capsule form. Aversion Technology opioid analgesic product candidates include a composition of commonly used active and inactive pharmaceutical ingredients. The Company conducts research, development, laboratory, manufacturing, and warehousing activities at its operations facility in Culver, Indiana and lease an administrative office in Palatine, Illinois. In addition to internal capabilities and activities, the Company engages numerous clinical research organizations (CROs) with expertise in regulatory affairs, clinical trial design and monitoring, clinical data management, biostatistics, medical writing, laboratory testing and related services. Such CROs perform, under its direction, development and regulatory services relating to its Aversion Technology product candidates.

Business Line
Engaged in research, development and manufacture of Aversion (abuse deterrent) Technology and related product candidates
Subsidiary
ACURA PHARMACEUTICAL TECHNOLOGIES, INC
Advisor
BDO
IPO date
3/17/1992
US SIC Code
2834
Company Address
Suite 120
616, N. North Court
City province or state postal code
60067, PALATINE, IL
Phone: +1 847 705 7709
Fax: +1 847 705 5399
Country address: UNITED STATES OF AMERICA
Website url: www.acurapharm.com